29 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? https://www.fool.com/investing/2024/03/13/does-this-1-new-threat-make-sarepta-therapeutics/?source=iedfolrf0000001 Mar 13, 2024 - The threat is still emerging, but it could be significant.
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study https://www.zacks.com/stock/news/2236810/regenxbio-rgnx-soars-15-on-interim-data-from-dmd-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236810 Mar 06, 2024 - Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y https://www.zacks.com/stock/news/2234137/sarepta-srpt-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2234137 Feb 29, 2024 - Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/02/29/sarepta-therapeutics-srpt-q4-2023-earnings-call-tr/?source=iedfolrf0000001 Feb 28, 2024 - SRPT earnings call for the period ending December 31, 2023.
Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates https://www.zacks.com/stock/news/2233462/sarepta-therapeutics-srpt-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2233462 Feb 28, 2024 - The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates? https://www.zacks.com/stock/news/2229472/sarepta-srpt-to-report-q4-earnings-will-it-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2229472 Feb 21, 2024 - Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release https://www.zacks.com/stock/news/2228601/sarepta-therapeutics-srpt-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2228601 Feb 20, 2024 - Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates? https://www.zacks.com/stock/news/2227756/can-rigel-pharmaceuticals-rigl-beat-q4-earnings-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227756 Feb 19, 2024 - Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow https://www.zacks.com/stock/news/2227548/corcept-cort-q4-earnings-beat-estimates-korlym-sales-grow?cid=CS-ZC-FT-analyst_blog|earnings_article-2227548 Feb 16, 2024 - Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits? https://www.zacks.com/stock/news/2227400/henry-schein-hsic-set-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227400 Feb 16, 2024 - Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.

Pages: 123

Page 1>